Kornimate/medical-research-clean huggingface dataset:
non-interventional open label prospective observational comparative study on evaluation of compliance of the empiric treatment with azithromycin sr versus amoxiclav 1000 mg in adult patients with mild to moderate community acquired pneumonia

Conditions: Community-Acquired Pneumonia

Summary: to compare compliance between patients with cap treated with azithromycin sr 2.0 g single dose orally and those treated with amoxiclav - 1000 mg twice daily 10 days for the empiric treatment of cap in outpatient clinic practice.


Eligibility criteria:
inclusion criteria: * males or not pregnant or lactating females, 18 years of age or older, for whom oral antibacterial therapy is indicated with clinically evidence of diagnosis of pneumonia, based on usual clinical practice: 1. physical examination and auscultatory findings (dullness on percussion, bronchial breath sounds, egophony, dry or fine most rales). 2. body temperature \>38 degrees c. exclusion criteria: * known or suspected hypersensitivity or intolerance or contraindications to azithromycin. * amoxiclav according to lpds, pregnant or lactating women.

Keywords: community-acquired pneumonia azithromycin sr amoxiclav
effect of virtual basrd reality training versus conservative treatment in chronic hemipretic stroke survivors

Conditions: Stroke

Summary: in hemiparetic stroke patient's vr is very useful. due to hemiparesis one side muscle weakness occurs because of disruption in brain, spinal cord and nervous system technologies improvs motor activities of patients, by improvement in motor activities patients perform activities in better way.

the study's main aim is to check virtual reality's effect on conservative treatment in hemiparetic stroke patients.

Eligibility criteria:
inclusion criteria: * both ischemia and hemorrhagic stroke. * stroke patients who were in chronic phase diagnosed by physician were included in the study. exclusion criteria: * patient with the history of previous stroke attacks. * brainstem stroke * epilepsy * severely impaired communication and cognition * parkinson's disease and multiple sclerosis * other musculoskeletal and psychological disorder
acid base balance of icu patients with severe hypoalbuminemia, before and after an albumin infusion, using stewart approach

Conditions: Hypoalbuminemia; Adult ICU Patient; Stewart Approach for Acid Base Disorders; Human Albumin Perfusion

Summary: the primary purpose was to describe the acid base balance of icu patients with severe hypoalbuminemia using stewart's approach for acid base disorders, before and after an human albumin perfusion.

prospective study, for icu patient with severe hypoalbuminemia \< 20g/l, determining biological parameters from stewart approach for acid base disorders (ph, side, sida, sig, atot, paco2) before, and at 1hour, 2hours and 24 hours after a 200ml 20% human albumin perfusion (the consensus conference anaes of 1995 recommands to correct hypoalbuminemia below 20g/l). clinical parameters (respiratory, haemodynamic, neurologic) were also collected at the same times.

Eligibility criteria:
inclusion criteria: * serum albuminemia \< 20g/l * adult icu patient * arterial line exclusion criteria: * albumin allergy * pregnancy * congestive heart failure

Keywords: hypoalbuminemia -acid base balance acid base disorders critical ill stewart approach human albumin infusion
prevention of altitude illness with non-steroidal anti-inflammatory study (pains)

Conditions: Altitude Sickness

Summary: this is a research study on altitude illness. from the information collected and studied in this project we hope to learn more about altitude illness, including factors that may affect and prevent the development and progression of this condition. we hope to learn if the commonly used non-steroidal anti-inflammatory medication, ibuprofen can prevent altitude illness. possible participants in this study are healthy adults who indicated they would like to participate, learn about altitude illness, and desire to hike barcroft peak. stanford university researchers hope to enroll about 100 participants.

this study was designed to bring together elements of prior studies and go one step further for definitive data on several points. the trial will employ two pharmaceutical intervention arms, which will compare placebo (the standard of care - information on prevention of altitude sickness) with the widely used nsaid ibuprofen. we will also determine optic nerve sheath diameter (onsd) measurements via ultrasound in both the control and interventional arms. we will accomplish these objectives with a prospective, double blinded view of a large population of hikers who are ascending at their own rate in a true hiking environment: the white mountain research station owen valley lab (ovl) and bancroft station (bar). primary hypothesis: ibuprofen 600 mg tid will be superior to placebo in decreasing both the incidence and severity of ams in high altitude travel.

Eligibility criteria:
inclusion criteria: 1. healthy male or female volunteer 2. age 18-65 3. sea-level dwelling 4. non pregnant 5. have not been to high altitude in the past week 6. can arrange for their own transportation to wmrs by friday evening the weekend of their study enrollment and are available the duration of the weekend of their study enrollment exclusion criteria: 1. age \ 65 2. live at altitude \> sea level +/- 1000' 3. pregnant 4. taking nsaids, acetazolamide, or corticosteroids 5. allergic to nsaids or aspirin, or have had adverse reaction to them in the past 6. traveled or planning to travel to high altitude in the week prior to their enrollment. 7. medical history of brain tumor, increased intercranial pressure, pseudotumor cerebri, ventricular shunts, loss of an eye, asthma, hace or hape. 8. cannot arrange for their own transportation to wmrs or are unavailable for the duration of the weekend of their study enrollment
the association between preoperative cpex and postoperative morbidity following oesophagectomy

Conditions: Oesophageal Cancer

Summary: a retrospective hospital-based cohort study of the association between preoperative cardiopulmonary exercise test (cpex) variables and short-term postoperative morbidity following oesophagectomy.

the aim of this study is to examine the correlations between preoperative cpex variables (vo2max and anaerobic threshold) and 30 day postoperative all cause morbidity in a sample large enough to allow (should significant associations exist) calculation of a threshold value. secondary aims are to examine associations between the vo2max, at and cardiopulmonary, non-cardiopulmonary complications as well as specific complications (atrial fibrillation, pneumonia, and anastomotic leak) as well as 30 and 90 day mortality.

Eligibility criteria:
inclusion criteria: i. male and female ii. underwent an oesophagectomy iii. completed a pre-operative cpex test exclusion criteria: i. patients that were unable to complete a full cpex test ii. emergency or palliative surgery iii. pharyngolaryngo-oesophagectomy iv. oesophagectomy and gastrectomy
dobutamine during major abdominal surgery

Conditions: Intraoperative Myocardial Depression

Summary: the push-1 trial is a randomized, single-center pilot trial investigating whether dobutamine administration is feasible in patients having major abdominal surgery.


Eligibility criteria:
inclusion criteria: * consenting patients ≥18 years scheduled for elective major abdominal surgery under general anesthesia (expected surgery duration ≥ 120 minutes) * planned continuous intraarterial blood pressure monitoring using an arterial catheter for clinical indications not related to the trial exclusion criteria: * emergency surgery * liver or kidney transplantation surgery * status of post transplantation of kidney, liver, heart, or lung * pregnancy * heart rhythms other than sinus rhythm
stress, dietary lapse and weight loss among adults with type 2 diabetes

Conditions: Obesity; Type 2 Diabetes

Summary: a clinical trial that uses personal digital assistants (pdas) to assist in examining the relationship between self reported stress, an objective biochemical indicator of stress (salivary alpha amylase) and self-reported dietary lapse among type 2 diabetic adults who are interested/undergoing in weight loss.

in the study, all participants will be provided with a personalized ada-based diet plan and a pre-programmed pda. they will be required to record their mood and activities into the pda whenever pda prompts, they break their diet plan, and/or and face significant stress. they will also be required to collect saliva samples periodically. in addition to this they will be administered the trier social stress test once during the study, where they will perform certain stress inducing tasks like delivering a speech and solving maths problems. salivary samples will be collected before and after these tasks. they will also take various questionnaires during each of the 15 to 16 visits. the completed questionnaires, pda records and reports of salivary alpha amylase levels will be analyzed to examine the corelation between stress, dietary lapse and weight loss.

Eligibility criteria:
inclusion criteria: * age 21 to 65 years, seeking weight loss. * type 2 diabetes diagnosis by american diabetes association standard criteria. (confirmed by physician's note or blood glucose reports in previous year or prescriptions for medications to control blood glucose dated in participant's name within last year). * bmi \> 30 kg/m2. exclusion criteria: * major depression. * cognitive impairment severe enough to preclude informed consent or valid self report. * use of medications that significantly affect appetite. * eating disorder. * inability or unwillingness to use pda for 6 months. * inability or unwillingness to collect saliva samples.

Keywords: type 2 diabetes obesity weight loss pda stress dietary lapse salivary alpha amylase
cerebral blood flow during cpb during cardiac surgery and the presence of post op delirium

Conditions: Delirium

Summary: cardiac surgery is associated with multiple events and issues that increase risk for adverse postoperative neurological outcomes including postoperative cognitive dysfunction. the risk for postoperative delirium is generally thought to result from some previous health factors added to the susceptibility of the cardiac surgery process.

cardiac surgery is associated with multiple perturbations that increase risk for adverse postoperative neurological outcomes including postoperative cognitive dysfunction. these same perturbations likely also increase the risk for postoperative delirium although there are little data that have evaluated this hypothesis. as the subject is prepared for surgery 2 contact probes will be placed on the forehead to monitor the rso2 and cerebral blood flow. this monitor can also measureblood flow velocity in blood vessels in the forehead. this will only be done while the subject is on the cardiac bypass machine during the surgery and end shortly after entering the intensive care unit.prior to surgery and then once a day on three of the first four postoperative days, patients will be assessed for the presence and severity of delirium with brief standard psychological exams. we will compare rso2 and cbf changes between patients with and without delirium

Eligibility criteria:
inclusion criteria: * patients in the study will be 50 or older undergoing elective cardiovascular surgery using cardiopulmonary bypass. * patients who can speak, read and understand the english language. * patients who understand the nature of the study and are willing to sign the consent form exclusion criteria: * emergency surgery or patients intubated before surgery and, thus, cannot give informed consent. * patients diagnosed with neurocognitive disorders (e.g. alzheimer's, dementia) * mmse score greater than 21 patients taking antipsychotic drugs a history of drug abuse * patients with an implant in the brain underneath the cerox probes * women who are pregnant. * history of significant, prohibitive skin allergies or reactions-

Keywords: cbf autoregulation, rso2,doppler, tcd, delirium,
romiplostim, rituximab and dexamethasone as frontline treatment for immune thrombocytopenia

Conditions: Immune Thrombocytopenia; Thrombotic Thrombocytopenic Purpura

Summary: the purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab, romiplostim and high-dose dexamethasone.

immune thrombocytopenia is an autoimmune disorder characterized by formation of autoantibodies against platelet antigens leading platelet destruction. corticosteroids increase the platelet count in about 80 percent of patients. however, many patients have a relapse when the dose of corticosteroid is reduced. debilitating side effects are common in patients who require long-term corticosteroid therapy to maintain the platelet count. romiplostim, it is a small molecule agonist of the c-mpl (tpor) receptor, which is the physiological target of the hormone thrombopoietin, has been shown to be effectively raise the platelet count in adult patients (aged 18 years and over) who have had their spleen removed or where splenectomy is not an option and have received prior treatment with corticosteroids or immunoglobulins, and these medicines did not work (refractory itp). there are a few case reports where romiplostim an option as first line treatment for it. the purpose of this study is to determine the response rate and response duration with the combination of rituximab (100 mg weekly four weeks), romiplostim (2mcg/kg four weekly) and high-dose dexamethasone (40mg po days 1-4) in untreated adult patients with \<30\*109/l platelet count diagnosed with immune thrombocytopenia. a complete response is defined as an increase in platelet counts to \>150×109/l on two consecutive occasions. a clinical response is defined as an increase in the platelet count between \>30×109/l on two consecutive measures and no bleeding. duration of response is considered from the day of the initial administration to the first time of relapse (platelet count \<30×109/l) or to time of analysis patients will be evaluated each week during 4 weeks and then every month for at least 6 months.

Eligibility criteria:
inclusion criteria: * clinically confirmed immune thrombocytopenia (it) platelet count less than 30,000/mm3 on two occasions. * subject ≥ 16 years * subject has signed and dated written informed consent. exclusion criteria: * previous treatment (only corticosteroids at dose or prednisone equivalent of 300 mg) * performance status above or equal to 2. * pregnancy and lactation * previous splenectomy * connective tissue disease * autoimmune hemolytic anemia * relapse * active infection, sepsis or fever * positive for hepatitis b virus or hepatitis c virus or human immunodeficiency virus.

Keywords: thrombocytopenia
phenylbutyrate in proteinuric nephropathies

Conditions: Proteinuric Diseases

Summary: the purpose of this study is to determine whether sodium phenylbutyrate can reduce lcn2 urinary expression in proteinuric patients.

proteinuria is a major prognosis factor of chronic kidney disease (ckd) progression. convergent evidences from clinical and experimental studies indicate that albuminuria and proteinuria are not simply a marker of ckd progression, but an active player in the evolution of the disease. mechanistically, it has been shown that proteinuria induces endoplasmic reticulum stress in tubular cells, leading to induction of lipocalin 2/ngal, a critical element of ckd progression. moreover, proteinuric mice treated with phenylbutyrate are protected from ckd progression. the aim of this study is to evaluate the efficacy of phenybutyrate, a molecular chaperone which inhibits er stress, on the proteinuria-induced ngal expression. urinary ngal/creatinine ratio will be evaluated in proteinuric patients before and under treatment with phenylbutyrate.

Eligibility criteria:
inclusion criteria: * chronic kidney disease for ore than 3 months * proteinuria \> 1g/d or 0,1g/mmmol creatinine * egfr \>30ml/mn/1,73m2 * written informed consent * affiliated with social security health insurance exclusion criteria: * women with childbearing potential * recent (\<3 months) modification of ace inhibitors or arb * acute renal failure * egfr \<30ml/mn/1,73m2 * nephrotic syndrome (albuminélia \<30g/l) * infection with hiv, hcv, hbv * liver insufficiency * no affiliated with social security health insurance * inclusion in another protocol of biomedical research * risk of non-adherence to protocol and visits * patients having a cardiac insufficiency of grade 3 or 4 * patient requiring of a strict salt-free diet * patients under corticoids or immunosuppresseurs * clinical intolerance in the treatment * intolerance in the fructose, the syndrome of malabsorption glucose and galactose or a deficit in sucrase / isomaltase * patients treated by probenecide

Keywords: proteinuria lipocalin 2 neutrophil gelatinase associated lipocalin elisa
ischemic stroke in chinese young adults

Conditions: Ischemic Stroke

Summary: stroke is the fifth leading cause of death in the united states and the leading cause of disability. however, in china, stroke is one of the most frequent causes of death and chronic disability. ischemic strokes in adults younger than 45 years of age were regarded as a relatively uncommon event in the proportion of \<5% of all ischemic strokes.

currently, stroke is the fifth leading cause of death in the united states and the leading cause of disability. however, in china, stroke is one of the most frequent causes of death and chronic disability. ischemic strokes in adults younger than 45 years of age were regarded as a relatively uncommon event in the proportion of \<5% of all ischemic strokes. our study aimed to evaluate some biomarkers underlying in ischemic stroke in chinese young adults.

Eligibility criteria:
inclusion criteria: * patients between 18 and 45 years of age with a first ever ischaemic stroke are eligible for this study from the department of beijing chaoyang hospital between january 1, 2016 and december 31, 2016. * all patients were defined as a sudden loss of global or focal cerebral function that persisted with a probable vascular cause for 24h and confirmed by brain ct or mri. exclusion criteria: * the exclusion criteria will include patients with intracranial lesions or cerebrovascular disease (including cerebral venous sinus thrombosis) * history that have caused sequelae, such as movement disorders, mood disorders, cognitive dysfunction or speech problems; or individuals who are pregnant or breast feeding. * patients with serious diseases that are related to the heart, liver, kidney or haematopoietic system will not be allowed to participate.
primary wound closure using a limberg flap versus secondary wound healing following pilonidal sinus excision

Conditions: Pilonidal Sinus

Summary: to compare primary wound closure using a limberg flap with secondary (p.s.) wound healing following excision of a pilonidal sinus.

patients who gave their informed consent who had excision of pilonidal sinus were randomly assigned to group a (primary wound closure with a limberg flap) or to group b (open wound and p.s.wound healing).

Eligibility criteria:
inclusion criteria: * indication for excision of pilonidal sinus given exclusion criteria: * limberg flap not possible for surgical reasons

Keywords: pilonidal sinus excision primary wound closure limberg flap
combined functional electrical stimulation & robotic gait training for children with cerebral palsy

Conditions: Cerebral Palsy

Summary: the purpose of this research study is to learn more about the usefulness of a physical therapy treatment that combines robot-assisted walking with electrical impulses that help to make muscles contract. this treatment is intended for children with cerebral palsy. up to eleven children with cerebral palsy will receive up to 18 treatments and will have several evaluations before and after treatment.


Eligibility criteria:
inclusion criteria: * gmfcs ii, iii, or iv cerebral palsy * 5-12 years of age * meet safety criteria for robotic gait training (\<300 lbs, intact skin, femoral length 21-47 cm, ability to follow simple instructions) * meet safety criteria for functional electrical stimulation (voluntary hip and knee muscle contraction, intact skin) exclusion criteria: * planned major intervention during study period * contractures that interfere with upright stance * history of non-traumatic long bone fracture or clinically significant osteoporosis * significant concurrent illness * significant condition not typically associated with cerebral palsy

Keywords: cerebral palsy gait training robotic functional electrical stimulation
reducing surgical site infection rates using an alternative sternal dressing

Conditions: Wound of Skin

Summary: this study will evaluate two alternative dressings compared to a standard island dressing presently in use at stanford hospital to determine reductions in surgical site infection (ssi) rates among cardiac surgery patients. cardiovascular surgery patients who will have a sternotomy incision as a routine part of their surgery will be approached to voluntarily participate. participants will be randomized to one of three dressing to determine which dressing has the lowest rate of sternal wound infection. the investigators will also assess the impact of alternative dressing use on hospital 30-day readmission rates related to ssi.


Eligibility criteria:
inclusion criteria: * participants who will undergo cardiac surgery via a sternotomy incision.inclusion criteria will be patients having surgical valve, cabgs, aortic dissection, myectomy and myotomy, cox maze, myocardial bridge un-roofing exclusion criteria: * patients undergoing heart transplants, ventricular assist device (vad), with postoperative courses complicated by tamponade, take-backs, and open chest incisions will also be excluded.